BBI’s purchase of Maine Biotechnology Services adds 80 antibodies to portfolio
17 Jan 2018
Cardiff-based BBI Solutions has added more than 80 antibodies to its product portfolio following the recent acquisition of the US company Maine Biotechnology Services (MBS) in Portland.
The purchase also adds custom antibody development services to BBI’s provision. The British company already provides human antigens, antibodies, serum and plasma products and clinical chemistry enzymes for the in-vitro diagnostics market.
BBI’s commercial manager for antibodies, Dr James Steggles, commented: “The acquisition of MBS gives us an opportunity to significantly grow our portfolio of antibodies to a wide variety of targets, while still maintaining the performance and quality standards our customers expect from us.”
The new antibodies in the BBI portfolio already appear in more than 50 FDA-approved kits and include antibodies to infectious diseases, inflammation, cardiac, hormone, immunoglobulins and assay control targets.
New infectious disease markers include Rotavirus, RSV, Adenovirus, Chikungunya, Mycoplasma pneumoniae, H. pylori, as well as a comprehensive panel of monoclonal antibodies specific for Norovirus.
In addition, BBI now offers immunoglobulin antibodies, a variety of hormone specificities, and popular biomarkers such as Lactoferrin, Myeloperoxidase, Cystatin C and Osteopontin.
Founded by John Chandler of Cardiff University in 1986, BBI began as Biocell Research Laboratories. In 2000 MD Julian Barnes led a management buyout. It opened a US office five years later and, last year, a legal facility in China.
In 2008 the company was purchased by Alere which sold BBI to Exponent Private Equity in 2016.
